The electrochemical behavior of dissolved Fe2O2 in 82.5CaCl2-17.5KF (mole percent, %) was studied using cy clic voltammetry, chronoamperometry, and galvanostatic electrolysis at 827 ℃, and the deposits were charact...The electrochemical behavior of dissolved Fe2O2 in 82.5CaCl2-17.5KF (mole percent, %) was studied using cy clic voltammetry, chronoamperometry, and galvanostatic electrolysis at 827 ℃, and the deposits were characterized by XRD and SEM. Pure iron was deposited on a rotating cylinder (210 r/min) with a cell voltage less than -- 1.0 V. Deposition rate was controlled by diffusion on a molybdenum electrode. The diffusion coefficient of iron species Fe( Ⅲ ) in the melt at 827 ℃ was found to be 9.7×10^-5 cm^2/s.展开更多
Most patients with advanced non-small cell lung cancer (NSCLC) experienced mild to severe disease-related symptoms including fatigue, loss of appetite, chest pain, dyspnoea, cough and hemoptysis. These symptoms hamp...Most patients with advanced non-small cell lung cancer (NSCLC) experienced mild to severe disease-related symptoms including fatigue, loss of appetite, chest pain, dyspnoea, cough and hemoptysis. These symptoms hamper the patients' ability to carry out daily activity and the deteriorating of disease-related symptoms is often associated with poor performance status, which may decrease the treatment options for patients. Furthermore,展开更多
基金Item Sponsored by National Natural Science Foundation of China(50674027)
文摘The electrochemical behavior of dissolved Fe2O2 in 82.5CaCl2-17.5KF (mole percent, %) was studied using cy clic voltammetry, chronoamperometry, and galvanostatic electrolysis at 827 ℃, and the deposits were characterized by XRD and SEM. Pure iron was deposited on a rotating cylinder (210 r/min) with a cell voltage less than -- 1.0 V. Deposition rate was controlled by diffusion on a molybdenum electrode. The diffusion coefficient of iron species Fe( Ⅲ ) in the melt at 827 ℃ was found to be 9.7×10^-5 cm^2/s.
文摘Most patients with advanced non-small cell lung cancer (NSCLC) experienced mild to severe disease-related symptoms including fatigue, loss of appetite, chest pain, dyspnoea, cough and hemoptysis. These symptoms hamper the patients' ability to carry out daily activity and the deteriorating of disease-related symptoms is often associated with poor performance status, which may decrease the treatment options for patients. Furthermore,